GlassScriptPhysician profile
Lindsey E Mccaskill
NPI 1932751724
$1,949.98
in general payments reported to CMS, 2019-2025
21 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $268 · 2022: $146 · 2023: $455 · 2024: $586 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $743.45 | 2021-2025 | |
| Lilly USA, LLC | $273.16 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Corium, LLC | $148.75 | 2023-2025 | Azstarys |
| Novo Nordisk INC | $135.35 | 2022-2025 | Ozempic, Rybelsus |
| Ironshore Pharmaceuticals INC. | $80.26 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $75.19 | 2023-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $57.47 | 2021 | |
| Axsome Therapeutics, INC. | $49.60 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.38 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $45.11 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $40.87 | 2022 | |
| Amgen INC. | $34.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $34.82 | 2021-2023 | Spravato |
| Astrazeneca Pharmaceuticals LP | $32.70 | 2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $29.42 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $27.14 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.56 | 2021 | |
| Lundbeck LLC | $21.56 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $17.92 | 2021 | |
| Acerus Pharmaceuticals Corporation | $15.48 | 2022 | |
| Antares Pharma, INC. | $14.87 | 2024 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Mccaskill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.